Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate- or prolonged-release tacrolimus

K. Vondrak, F. Parisi, A. Dhawan, R. Grenda, NJA. Webb, SD. Marks, D. Debray, RCL. Holt, A. Lachaux, D. Kelly, G. Kazeem, N. Undre,

. 2019 ; 33 (10) : e13698. [pub] 20190919

Jazyk angličtina Země Dánsko

Typ dokumentu klinické zkoušky, fáze II, srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025602

Grantová podpora
Department of Health - United Kingdom

BACKGROUND AND AIMS: This multicenter trial compared immediate-release tacrolimus (IR-T) vs prolonged-release tacrolimus (PR-T) in de novo kidney, liver, and heart transplant recipients aged <16 years. Each formulation had similar pharmacokinetic (PK) profiles. Follow-up efficacy and safety results are reported herein. MATERIALS AND METHODS: Patients, randomized 1:1, received once-daily, PR-T or twice-daily, IR-T within 4 days of surgery. After a 4-week PK assessment, patients continued randomized treatment for 48 additional weeks. At Year 1, efficacy assessments included the number of clinical acute rejections, biopsy-confirmed acute rejection (BCAR) episodes (including severity), patient and graft survival, and efficacy failure (composite of death, graft loss, BCAR, or unknown outcome). Adverse events were assessed throughout. RESULTS: The study included 44 children. At Year 1, mean ± standard deviation tacrolimus trough levels were 6.6 ± 2.2 and 5.4 ± 1.6 ng/mL, and there were 2 and 7 acute rejection episodes in the PR-T and IR-T groups, respectively. No cases of graft loss or death were reported during the study. The overall efficacy failure rate was 18.2% (PR-T n = 1; IR-T n = 7). CONCLUSIONS: In pediatric de novo solid organ recipients, the low incidence of BCAR and low efficacy failure rate suggest that PR-T-based immunosuppression is effective and well tolerated to 1-year post-transplantation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025602
003      
CZ-PrNML
005      
20201222160310.0
007      
ta
008      
201125s2019 dk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/ctr.13698 $2 doi
035    __
$a (PubMed)31436896
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a dk
100    1_
$a Vondrak, Karel $u University Hospital Motol, Prague, Czech Republic.
245    10
$a Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate- or prolonged-release tacrolimus / $c K. Vondrak, F. Parisi, A. Dhawan, R. Grenda, NJA. Webb, SD. Marks, D. Debray, RCL. Holt, A. Lachaux, D. Kelly, G. Kazeem, N. Undre,
520    9_
$a BACKGROUND AND AIMS: This multicenter trial compared immediate-release tacrolimus (IR-T) vs prolonged-release tacrolimus (PR-T) in de novo kidney, liver, and heart transplant recipients aged <16 years. Each formulation had similar pharmacokinetic (PK) profiles. Follow-up efficacy and safety results are reported herein. MATERIALS AND METHODS: Patients, randomized 1:1, received once-daily, PR-T or twice-daily, IR-T within 4 days of surgery. After a 4-week PK assessment, patients continued randomized treatment for 48 additional weeks. At Year 1, efficacy assessments included the number of clinical acute rejections, biopsy-confirmed acute rejection (BCAR) episodes (including severity), patient and graft survival, and efficacy failure (composite of death, graft loss, BCAR, or unknown outcome). Adverse events were assessed throughout. RESULTS: The study included 44 children. At Year 1, mean ± standard deviation tacrolimus trough levels were 6.6 ± 2.2 and 5.4 ± 1.6 ng/mL, and there were 2 and 7 acute rejection episodes in the PR-T and IR-T groups, respectively. No cases of graft loss or death were reported during the study. The overall efficacy failure rate was 18.2% (PR-T n = 1; IR-T n = 7). CONCLUSIONS: In pediatric de novo solid organ recipients, the low incidence of BCAR and low efficacy failure rate suggest that PR-T-based immunosuppression is effective and well tolerated to 1-year post-transplantation.
650    _2
$a mladiství $7 D000293
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a rejekce štěpu $x farmakoterapie $x etiologie $7 D006084
650    _2
$a přežívání štěpu $x účinky léků $7 D006085
650    _2
$a lidé $7 D006801
650    _2
$a imunosupresiva $x terapeutické užití $7 D007166
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a transplantace orgánů $x škodlivé účinky $7 D016377
650    _2
$a pooperační komplikace $x farmakoterapie $x etiologie $7 D011183
650    _2
$a prognóza $7 D011379
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a rizikové faktory $7 D012307
650    _2
$a míra přežití $7 D015996
650    _2
$a takrolimus $x terapeutické užití $7 D016559
650    _2
$a příjemce transplantátu $x statistika a číselné údaje $7 D066027
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Parisi, Francesco $u Ospedale Pediatrico Bambino Gesù, Rome, Italy.
700    1_
$a Dhawan, Anil $u King's College Hospital, London, UK.
700    1_
$a Grenda, Ryszard $u The Children's Memorial Health Institute, Warsaw, Poland.
700    1_
$a Webb, Nicholas J A $u Manchester University Foundation Trust, Manchester, UK.
700    1_
$a Marks, Stephen D $u Great Ormond Street Hospital for Children, NHS Foundation Trust, London, UK.
700    1_
$a Debray, Dominique $u APHP-Hôpital Universitaire Necker, Paris, France.
700    1_
$a Holt, Richard C L $u Alder Hey Children's Hospital, Liverpool, UK.
700    1_
$a Lachaux, Alain $u Université Lyon 1 et Hospices Civils de Lyon, Lyon, France.
700    1_
$a Kelly, Deirdre $u Birmingham Women's & Children's Hospital, Birmingham, UK.
700    1_
$a Kazeem, Gbenga $u Astellas Pharma Europe Ltd, Chertsey, UK. BENKAZ Consulting Ltd, Cambridge, UK.
700    1_
$a Undre, Nasrullah $u Astellas Pharma Europe Ltd, Chertsey, UK.
773    0_
$w MED00001167 $t Clinical transplantation $x 1399-0012 $g Roč. 33, č. 10 (2019), s. e13698
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31436896 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222160305 $b ABA008
999    __
$a ok $b bmc $g 1599747 $s 1116288
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 33 $c 10 $d e13698 $e 20190919 $i 1399-0012 $m Clinical transplantation $n Clin Transplant $x MED00001167
GRA    __
$p Department of Health $2 United Kingdom
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace